Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
iCaD Study
2022-503026-12-00Phase 3Authorised
- Sponsor
- University Hospital Odense
- Start
- May 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 2
01
Overview
Phase 3, randomised, open-label trial of infliximab in immune-mediated colitis and diarrhea (2 arms), sponsored by University Hospital Odense. Primary endpoint: Time to persistent grade ≤1 immune-related colitis/diarrhoea. Planned start May 2023; status: authorised.
02
Drugs
infliximab
03
Conditions
immune-mediated colitisdiarrhea
Beyond the preview
Go deeper on 2022-503026-12-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-503026-12-00.